The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics and Biogen published NEJM data showing that the antisense oligonucleotide zorevunersen produced substantial, durable reductions in seizures and sustained improvements in cognition and behavior through three years in Phase 1/2a and open‑label extension cohorts (N=81), with the largest seizure reductions observed at 70 mg. Safety was generally tolerable across >800 doses administered, though CSF protein elevations were common in OLEs (44%, n=33/75) with one discontinuation; one patient experienced suspected unexpected serious adverse reactions. The program has orphan, rare pediatric and Breakthrough Therapy designations, Stoke retains U.S./Canada/Mexico rights (Biogen holds rest‑of‑world), and the global Phase 3 EMPEROR study (N≈150) is on track to complete enrollment in Q2 2026 with a mid‑2027 data readout that would support an NDA—an outcome that could be a material value inflection for Stoke and relevant to Biogen’s rare‑disease portfolio.

Analysis

Market structure: NEJM validation makes Stoke (STOK) the direct beneficiary of a potential first-in-class disease‑modifying SCN1A ASO, with Biogen (BIIB) capturing most ex‑US commercialization value; the addressable prevalence (~38k in US/UK/EU/Japan) implies high price-per-patient economics and strong initial pricing power but limited unit volume. Incumbent ASM vendors face modest demand erosion because zorevunersen targets underlying biology and could command premium reimbursement; early supply will be constrained (intrathecal manufacturing/logistics), creating short-term scarcity and favorable pricing dynamics.

Risk assessment: The largest tail risks are a negative EMPEROR readout (mid-2027) or regulatory safety hold driven by CSF protein elevations (44% in OLE) or the single SUSAR; manufacturing scale-up and payer refusal to accept high chronic ASO pricing are material. Time buckets: immediate (days) = volatility and re‑rating of STOK; short (Q2 2026) = enrollment completion and any DSMB signals; medium (mid‑2027) = pivotal readout; long (2028+) = commercial launch, reimbursement negotiation and uptake curves.

Trade implications: Favor asymmetric exposure—concentrated equity or call-spread exposure to STOK sized 2–3% of portfolio with downside hedges (18‑24 month 25% OTM puts sized ~30% of equity notional); complement with a modest 1–2% BIIB 24‑month call spread (buy +10% OTM, sell +40% OTM) to capture ex‑US upside while limiting capital. Implied vol for STOK will stay elevated; use calendar or diagonal spreads to buy time if you want exposure while financing premium; rotate away from speculative micro‑caps in epilepsy lacking Phase‑3 validation.

Contrarian angles: The market may over‑extrapolate open‑label OLEs—blinded EMA/FDA scrutiny typically downgrades effect sizes, so current optimism could be overdone before week‑28 blinded effects are confirmed. Conversely, Biogen’s rest‑of‑world rights and commercial infrastructure are likely underpriced vs. STOK’s binary risk; expect pricing negotiations and outcomes‑based contracts to materially affect realized revenue versus headline prevalence-based models. Historical parallel: Spinraza showed rapid uptake then pricing scrutiny—prepare for a similar two‑stage valuation path.

Key Decisions for Investors

• Establish a 2–3% long equity position in STOK ahead of the EMPEROR readout (mid‑2027); protect with 18–24 month 25% OTM puts sized at ~30% of the equity notional; set a partial profit target of +50% and a hard stop‑loss at −30%.
• Deploy 1–2% of capital into a BIIB 24‑month call spread to capture ex‑US commercialization upside (buy a +10% OTM 24‑month call, sell a +40% OTM 24‑month call); roll or exercise if regulatory filings occur by end‑2027.
• After STOK completes enrollment (expected Q2 2026), sell 3‑month covered calls up to +15% premium to monetize elevated IV on rallies; redeploy proceeds into incremental STOK long exposure if implied vol falls >30% post‑enrollment.
• Reduce exposure to speculative small‑cap epilepsy/ASO peers by ~20% across the book and reallocate that capital into the STOK/BIIB trades and a diversified rare‑disease biotech theme (target +3% overweight vs. benchmark) to concentrate on validated platforms.